NYC Mayor Eric Adams Launches Operation Padlock to Protect City

Regulations by 2FIRSTS.ai

May.08.2024

NYC Mayor Eric Adams Launches Operation Padlock to Protect City

NYC Mayor Eric Adams launches Operation Padlock to Protect, shutting down unauthorized tobacco and marijuana shops in five boroughs.

According to Fox5ny on May 7th, Mayor Eric Adams of New York City announced on Tuesday the launch of a project called "Operation Padlock to Protect," which will close all unauthorized tobacco and marijuana stores in five boroughs of the city. This move comes after the state government granted new powers to local governments in the new state budget.

The Adams administration has made it clear that any businesses operating illegally will quickly face legal consequences. This measure aims to protect the city's children, improve quality of life, and promote the safe prosperity of the legal marijuana market.

Thanks to Governor Kathy Hochul and our collaboration with the state legislature, each neighborhood in New York City is now using the law to protect our streets. Legal cannabis remains the right choice for our city, but for those who choose to break the law, we will shut down your shop.

According to a press release, the city government has filed lawsuits against 15 e-cigarette retailers and convenience stores from last summer to last month. The Mayor's Office stated that the "Lock It Up" initiative will be rapidly implemented in the coming weeks.

References:

[1] NYC Mayor to shut down of unlicensed smoking, cannabis stores in all boroughs

Also Read:

[1] New Regulations on Marijuana Cultivation and Storage in New York

[2] New York State to Issue 1445 New Cannabis Licenses

[3] Crackdown on Illegal Marijuana Shops in New York City

#Law enforcement #North America #United States #Traditional tobacco #USA

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

BAT Pauses U.S. Launch of Unlicensed Vuse One Vape amid FDA Crackdown — Reuters

British American Tobacco has paused the U.S. pilot launch of its unlicensed Vuse One vape amid intensified FDA enforcement.

Oct.28 by 2FIRSTS.ai

U.S. Nicotine Pouch Sales Surge, Forcing Convenience Stores to Rethink Backbar Layouts

U.S. convenience stores are restructuring backbar displays as nicotine pouches and other modern oral products gain space amid regulatory and product-mix shifts. The New York Association of Convenience Stores reports nicotine pouch sales are up over 40% this year, while some chains are trimming cigarette facings and testing zero-nicotine and herbal alternatives.

Dec.04 by 2FIRSTS.ai

KT&G Q3 Net Profit Up 73%; Overseas NGP Revenue Nearly Doubles, Nicotine Pouch Expansion Set to Launch Globally

KT&G reported its Q3 2025 financial results, posting revenue of KRW 1.83 trillion (≈USD 1.31 billion) and a 73.4% year-over-year surge in net profit—marking the company’s highest operating profit in five years. The Next Generation Product (NGP) segment performed strongly, generating KRW 279.1 billion (≈USD 199 million) in revenue, with overseas NGP sales more than doubling year-over-year.